Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00
Provider: Thomson Reuters StreetEvents
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

STADA Arzneimittel AG Confirms FY 2013 and FY 2014 Guidance


Wednesday, 13 Nov 2013 01:25am EST 

STADA Arzneimittel AG (STADA) announced that it confirms the outlook for the future development of the STADA Group published at the beginning of 2013. The Executive Board thus expects further growth in Group sales for 2013. The Executive Board thereby expects that sales growth can be achieved in both core segments in 2013, in the context of which the Branded Products core segment is expected to grow at a disproportionate rate, so that the share of branded products in Group sales will continue to grow. Furthermore, the Executive Board sees the opportunity for further growth in the Group's adjusted EBITDA in the high single-digit percent area in 2013 and thereby achieving a new record value. In addition, the Executive Board affirms the long-term prognosis envisaged for the fiscal year 2014, according to which Group sales of approximately EUR 2.15 billion, at an adjusted level, EBITDA of approximately EUR 430 million and net income of approximately EUR 215 million should be reached at minimum. 

Company Quote

25.75
-0.17 -0.66%
19 Dec 2014